Literature DB >> 1859301

Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey.

F E Somnier1, N Keiding, O B Paulson.   

Abstract

The incidence of myasthenia gravis (MG) was found to be constant in calendar time. The mean annual incidence rate was 4.4 per million population. Age- and sex-specific incidence rates disclosed a bimodal appearance for both sexes, with a peak age at onset located in the early-onset group and another peak for late onset of MG. Early onset of MG appeared 10 years later for male individuals than for female individuals, whereas the peak for late onset of MG was located at the same age for both sexes. It is suggested that the separation between early onset and late onset of MG should be at the age of 50 years for both sexes, rather than at 35 to 40 years as accepted in most studies. The prevalence of MG has increased in time. On January 1, 1988, the point prevalence rate was 77 per million population (female subjects, 96, and male subjects, 57). This reflects an improvement in prognosis despite the fact that life expectancy was found to be significantly lower for MG patients than that of the sex- and age-matched population. The factors causing increased mortality were found to be operative throughout the duration of the disease. Maximum severity of disease was reached within 2 years from onset in 78% of the cases, and more than 50% of all MG-related deaths occurred during the same period. In the course of MG, 70% of all patients experience generalized muscular weakness, and 30% to 40% also suffer from respiratory problems.

Entities:  

Mesh:

Year:  1991        PMID: 1859301     DOI: 10.1001/archneur.1991.00530190081019

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  21 in total

1.  Nationwide population-based epidemiological study of myasthenia gravis in taiwan.

Authors:  Chien-Hsu Lai; Hung-Fu Tseng
Journal:  Neuroepidemiology       Date:  2010-06-03       Impact factor: 3.282

2.  Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

Authors:  N Sommer; B Sigg; A Melms; M Weller; K Schepelmann; V Herzau; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

3.  Myasthenia gravis: a changing pattern of incidence.

Authors:  I Casetta; E Groppo; R De Gennaro; E Cesnik; L Piccolo; S Volpato; E Granieri
Journal:  J Neurol       Date:  2010-07-11       Impact factor: 4.849

Review 4.  A systematic review of population based epidemiological studies in Myasthenia Gravis.

Authors:  Aisling S Carr; Chris R Cardwell; Peter O McCarron; John McConville
Journal:  BMC Neurol       Date:  2010-06-18       Impact factor: 2.474

5.  Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001.

Authors:  J F Owe; A K Daltveit; N E Gilhus
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

6.  Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England.

Authors:  N P Robertson; J Deans; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-10       Impact factor: 10.154

7.  Effects of combined traditional Chinese medicine with immunosuppressive agents for patients with myasthenia gravis.

Authors:  Guoyan Qi; Shanshan Gu; Peng Liu; Hongxia Yang; Huimin Dong
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 8.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

9.  A population based epidemiological study on myasthenia gravis in Estonia.

Authors:  M Oöpik; A-E Kaasik; J Jakobsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-12       Impact factor: 10.154

10.  Epidemiological study of myasthenia gravis in the province of Reggio Emilia, Italy.

Authors:  D Guidetti; R Sabadini; M Bondavalli; S Cavalletti; M Lodesani; R Mantegazza; V Cosi; F Solime
Journal:  Eur J Epidemiol       Date:  1998-06       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.